Dr I. ELEGEERT SRL
The score of Dr I. ELEGEERT shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +79 % Total assets +76 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dr I. ELEGEERT's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Sep 2026
- Year ended 31 Dec 2024filed on 25 Aug 2025
- Year ended 31 Dec 2023filed on 02 Sep 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 29 Jul 2022
Dr I. ELEGEERT's financial analysis
- Solvency86.9%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dr I. ELEGEERT
Dr I. ELEGEERT's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0878.076.068
- VAT number
- BE0878076068
- Peppol
- Registered · 0208:0878076068 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 Dec 2005
- Registered office
- 8500 Kortrijk
- Latest accounts
- 2025 · filed on 08 Sep 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Dr I. ELEGEERT (SRL) has been based in Kortrijk since 2005, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 237,719 € and equity of €1.38m; its revenue is not published. Its solvency stands at 86.9%, above the median of its sector (60.4%).
Companies similar to Dr I. ELEGEERT
Companies in the same business, of comparable size and area, outside its group.
- Alanine Research and experimental development on natural sciences and engineering Lasne · balance sheet 28,321 €
- IQVIA Cancer Research Research and experimental development on natural sciences and engineering Zaventem · balance sheet €1.07m
- Bimsconsult Research and experimental development on natural sciences and engineering Auderghem · balance sheet 463,296 €
- Dr. Deroo - Dr. Vanneuville Research and experimental development on natural sciences and engineering Tielt · balance sheet €1.58m
- Dokter Brigitte Maes Research and experimental development on natural sciences and engineering Hasselt · balance sheet €1.65m
- Docteur Pierre Henri Arnould Research and experimental development on natural sciences and engineering Libramont-Chevigny · balance sheet €1.47m
- Normec Micro-Smedt Research and experimental development on natural sciences and engineering Herentals · balance sheet €1.75m
- Cardiac Research Institute Research and experimental development on natural sciences and engineering Aalst · balance sheet €1.86m
Frequently asked questions about Dr I. ELEGEERT
What is the revenue of Dr I. ELEGEERT?
Dr I. ELEGEERT files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dr I. ELEGEERT?
In Belgium, the VAT number is the company number prefixed with BE: BE0878076068 for Dr I. ELEGEERT, if the company is VAT-registered. Its company number (CBE) is 0878.076.068.
Where is the registered office of Dr I. ELEGEERT?
According to the CBE register, the registered office of Dr I. ELEGEERT is in 8500 Kortrijk.
What is the equity of Dr I. ELEGEERT?
At the close of the 2025 financial year, the equity of Dr I. ELEGEERT amounts to 1,380,563 €, a solvency of 86.9% of total assets.
Who manages Dr I. ELEGEERT?
The register lists 1 active mandates at Dr I. ELEGEERT. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dr I. ELEGEERT
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →